Adipocyte‐specific deletion of Mettl14 protects against diet‐induced obesity, NAFLD, and metabolic disease through increasing adipose β adrenergic signaling and lipolysis. This evidence concerns the gene METTL14 and metabolic dysfunction-associated steatotic liver disease.